ijÌ.

The state

1

- 11. Use according to claim 2 in which the medicament is for treatment of abdominal/visceral obesity.
- 12. Use according to claim 2 in which the medicament is for increase insulin sensitivity.
- 13. Use according to claim 2 in which the medicament is for decrease of insulin resistance.
- 14. Use according to claim 2 in which the medicament is for decrease of total body fat mass.
- 15. Use according to claim/2 in which the medicament is for decrease of total body fat in human with abdominal/visceral obesity.
- 16. Use according to claim 2 in which the medicament is for visceral adipose tissue area.
- 17. Use according to claim 2 in which the medicament is for decrease of serum concentration of triglyceride.
- 18. Use according to claim 2 in which the medicament is for decrease of diastolic blood pressure.

Remarks

The claims have been amended to eliminate multiple dependency and to improve their format. None of these amendments is believed to involve any new matter. Accordingly, it is respectfully requested that the foregoing amendments be entered, that the application as so